RT Journal Article
SR Electronic
T1 Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.07.20125096
DO 10.1101/2020.06.07.20125096
A1 Li, Yang
A1 Lai, Dan-yun
A1 Zhang, Hai-nan
A1 Jiang, He-wei
A1 Tian, Xiao-long
A1 Ma, Ming-liang
A1 Qi, Huan
A1 Meng, Qing-feng
A1 Guo, Shu-juan
A1 Wu, Yan-ling
A1 Wang, Wei
A1 Yang, Xiao
A1 Shi, Da-wei
A1 Dai, Jun-biao
A1 Ying, Tian-lei
A1 Zhou, Jie
A1 Tao, Sheng-ce
YR 2020
UL http://medrxiv.org/content/early/2020/06/09/2020.06.07.20125096.abstract
AB SARS-CoV-2 outbreak is a world-wide pandemic. The Spike protein plays central role in cell entry of the virus, and triggers significant immuno-response. Our understanding of the immune-response against S protein is still very limited. Herein, we constructed a peptide microarray and analyzed 55 convalescent sera, three areas with rich linear epitopes were identified. Potent neutralizing antibodies enriched from sera by 3 peptides, which do not belong to RBD were revealed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially supported by the National Key Research and Development Program of China Grant (No. 2016YFA0500600), National Natural Science Foundation of China (No. 31970130, 31600672, 31670831, and 31370813), Shenzhen Key Laboratory of Synthetic Genomics (ZDSYS201802061806209), Shenzhen Science and Technology Program (KQTD20180413181837372), Guangdong Provincial Key Laboratory of Synthetic Genomics (2019B030301006) and Foshan Scientific and Technological Key Project for COVID-19 (NO:2020001000430).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Ethics Review Committee of Foshan Fourth Hospital, Foshan, China approved this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe peptide microarray data are deposited on Protein Microarray Database (http://www.proteinmicroarray.cn) under the accession number PMDE242. Additional data related to this paper may be requested from the authors. http://www.proteinmicroarray.cn